Status message

Active context: kki_bg_colors_yellow

A 20-Week Double Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Rivastigmine in Children (ages 10-17) with Down syndrome

Principal Investigator:

The specific aims of this study are to: a) investigate short-term safety and efficacy of rivastigmine treatment; b) build upon the open-label treatment results of overall function and language improvement in children with Down syndrome (DS) in a double-blind, placebo-controlled clinical trial; and c) investigate other specific cognitive domains that may selectively respond to rivastigmine treatment.

Participate in Research:

If you or someone you know is interested in participating in this research study, please download this informational flyer.

Kennedy Krieger Institute Announces Retirement of President and CEO

Dr. Gary W. GoldsteinThe Institute’s board of directors is conducting a national search and is expected to name a new CEO in the coming months.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.